SK Bioscience Advances Universal Coronavirus Vaccine into Phase 1/2 Trials
Event summary
- SK Bioscience initiated a global Phase 1/2 clinical trial for GBP511, a universal vaccine targeting the Sarbecovirus family, including SARS-CoV-2 and related coronaviruses.
- The trial will enroll 368 adults in Australia, evaluating safety, tolerability, and immunogenicity across low-, medium-, and high-dose cohorts with or without an adjuvant.
- GBP511 leverages SKYCovione's recombinant protein-based platform and nanoparticle technology developed by the Institute for Protein Design.
- CEPI has designated the SARS-coronavirus family as a 'prototype pathogen' and supports the development of broadly protective coronavirus vaccines.
The big picture
SK Bioscience's entry into global Phase 1/2 clinical development for a universal coronavirus vaccine marks a significant step in pandemic preparedness. The company's technology, leveraging SKYCovione's platform and nanoparticle design, positions it as a leader in next-generation vaccine development. The global COVID-19 vaccine market is projected to grow at a CAGR of 7.4% from 2025 to 2032, driven by the need for broadly protective vaccines capable of addressing future coronavirus threats.
What we're watching
- Clinical Trial Progress
- The pace at which GBP511 advances through Phase 1/2 trials will determine its potential as a universal coronavirus vaccine.
- Market Dynamics
- Whether SK Bioscience can sustain mid- to long-term growth in the COVID-19 vaccine market amid shifting demand patterns.
- Regulatory Approval
- How regulatory authorities will evaluate the safety and efficacy of GBP511 compared to existing vaccines like Comirnaty.
Related topics